Two Phase 3, randomized, placebo-controlled, double-blind clinical trials testing whether experimental monoclonal antibodies (mAbs) can prevent infection by SARS-CoV-2 coronavirus are now enrolling healthy adults at clinical trial sites in the United States.
In a paper in the New England Journal of Medicine(link is external), scientific leaders from the National Institutes of Health set forth a framework to increase significantly the number, quality and type of daily tests for detecting SARS-CoV-2, the virus that causes COVID-19, and help reduce inequities for underserved populations that have been disproportionally affected by the disease.
Research shows that adolescents who live in areas that have high levels of artificial light at night tend to get less sleep and are more likely to have a mood disorder relative to teens who live in areas with low levels of night-time light. The research was funded by the National Institute of Mental Health (NIMH), part of the National Institutes of Health, and is published in JAMA Psychiatry.
A new study has begun recruiting at the National Institutes of Health in Bethesda, Maryland, to determine how many adults in the United States without a confirmed history of infection with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), have antibodies to the virus.
Billionaires are spending millions to fight the novel coronavirus that has infected more than 110,000 people and killed nearly 3,900 globally, including 22 reported deaths in the United States.
A research team led by Univ.-Prof. Dr. Florian Klein of the Institute of Virology of the University Hospital Cologne and the German Center for Infection Research (DZIF) has identified a new highly active antibody targeting HIV.
The visit of US Assistant Secretary for Fossil Energy, Steven Winberg, to this year’s Africa Oil Week event in Cape Town highlights the importance that the United States put in fostering relationships with the continent
